Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
22 drugs in development
By Therapeutic Area
top 6
R&D Momentum
88/100
Pipeline Velocity
63/100
Trial Completion Rate
76/100
Pipeline Concentration
21/100
Pipeline Freshness
68/100
Strategic Signals
Activity
Last 14 days
Control of Ventilation During Wakefulness in Opioid vs. Non-opioid Patients
Improving Postamputation Functioning by Decreasing Phantom Limb Pain and Opioid Use With Perioperative Continuous Peripheral Nerve Blocks: A Multicenter RCT
Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery: A Randomized, Observer and Participant Masked, Active Control, Non-Inferiority Study
Suzetrigine for Non-Mastectomy Breast Surgery: A Non-Randomized, Prospective Study With Historic Controls
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Meditation Accelerated Brain Stimulation for Depression
Developing and Testing a Brief, Personalized Intervention for Suicidal Thoughts and Behaviors
Targeting Food Cue Responsiveness for Weight Loss
Meditative Neurofeedback for Depression
Primary Care Referrals to a Remotely Delivered Physical Activity Intervention for Latina Teens: Chicas Fuertes 2
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)